A collaborative clinical study led by National Taiwan University Hospital (NTUH) and Taiwan Clinical Oncology Group, National Health Research Institutes (TCOG, NHRI) has yielded promising results for a new therapeutic regimen to treat primary central nervous system lymphoma (PCNSL), a rare and aggressive cancer that develops in the brain or other parts of the central nervous system.